Effects of Pregnane X Receptor (PXR) Activation on Human Glucose, Lipid and Hormone Homeostasis

University of Oulu12 enrolled

Overview

This clinical trial is designed to study the effects of pregnane X receptor activator rifampicin on the glucose, lipid and hormone homeostasis in healthy volunteers. The main hypothesis is that rifampicin raises postprandial glucose studied with oral glucose tolerance test. The study is a non-randomized, one-phase, open-label trial. Twelve subjects will be given 600 mg of rifampicin a day for a week. The main outcome measures are the changes in the glucose and insulin levels during oral glucose tolerance test.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Glucose Metabolism

Interventions

RifampicinDRUG

Rifampicin 600 mg daily for a week

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy volunteer * Age 18-45 years * Body mass index 19-28 Exclusion Criteria: * Any continuous medication * Any significant disease * Allergy to rifampicin * Pregnancy and breast feeding * Fear of needles and previous difficult blood samplings * Substance abuse * Participation in another clinical drug trial within 1 month of enrollment * Use of soft contact lenses

Locations (1)

Oulu University Hospital

Oulu, Finland

Outcomes

Primary Outcomes

Glucose levels during oral glucose tolerance test

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.